Safety studies in human volunteers
Single ascending dose safety and pharmacokinetics study
ODG members worked with the National Institutes of Health (NIAID/DMID) to conduct First in Human studies of oxfendazole, the first clinical step in the development of oxfendazole. The design and results of this safety and pharmacokinetics study are given under NCT02234570 on the ClinicalTrials.gov web site: https://clinicaltrials.gov/ct2/show/NCT02234570?term=oxfendazole&rank=2 The results of the Phase I Single Ascending Dose (SAD) study of oxfendazole are now published. See the safety profile and pharmacokinetics of oxfendazole in healthy volunteers: publication Phase I SAD study
Multiple ascending dose safety and pharmacokinetics study and food effect study
ODG is working with the National Institutes of Health (NIAID/DMID) in the conduct a multiple ascending dose safety and pharmacokinetics study of oxfendazole, as well as a food effect study. The design and results of these studies is given under NCT03035760 on the ClinicalTrials.gov web site: https://clinicaltrials.gov/ct2/show/NCT03035760?term=oxfendazole&rank=2 and published: Oxfendazole MAD study 2020.
Efficacy study in patients
Proof of concept study in patients
ODG holds an open IND for a Proof of Concept study of oxfendazole in patients infected with the geohelminth Trichuris trichiura, an intestinal worm. In this assessor blind, randomized Phase 2 study, the efficacy of different doses of oxfendazole will be compared to the efficacy of albendazole, the currently used medication. Albendazole is only moderately effective in curing T. trichiura infection. The design of this study is given under NCT03435718 on the Clinicaltrials.gov website: https://clinicaltrials.gov/ct2/show/NCT03435718?term=oxfendazole&rank=1